Af­ter get­ting hopes up, ex­pec­ta­tions on Gilead, Ar­cus' CD73 'dimmed' on new up­date

When you’ve got an al­liance as hefty as the one Ar­cus and Gilead have, every up­date counts.

That’s why the com­pa­nies found an­a­lysts frown­ing on the lat­est dis­clo­sure around quem­li­clu­s­tat, their small mol­e­cule in­hibitor of CD73. Al­though an in­ter­im analy­sis from a triplet com­bo tri­al in pan­cre­at­ic can­cer looks “promis­ing,” it didn’t seem that much dif­fer­ent from chemother­a­py alone — trig­ger­ing a de­ci­sion to wait for “more ma­ture” pro­gres­sion-free sur­vival and over­all sur­vival da­ta be­fore mak­ing a call.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER